KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to $755.6 million.

  • Sarepta Therapeutics' Cash from Investing Activities rose 280.40% to $232.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.6 million, marking a year-over-year increase of 1111.52%. This contributed to the annual value of $755.6 million for FY2024, which is 555.70% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Cash from Investing Activities of $755.6 million as of FY2024, which was up 555.70% from -$165.8 million recorded in FY2023.
  • Over the past 5 years, Sarepta Therapeutics' Cash from Investing Activities peaked at $755.6 million during FY2024, and registered a low of -$1.0 billion during FY2022.
  • For the 3-year period, Sarepta Therapeutics' Cash from Investing Activities averaged around -$152.4 million, with its median value being -$165.8 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 311.32% in 2022, then surged by 555.70% in 2024.
  • Sarepta Therapeutics' Cash from Investing Activities (Yearly) stood at -$121.7 million in 2020, then soared by 507.01% to $495.4 million in 2021, then slumped by 311.32% to -$1.0 billion in 2022, then soared by 84.16% to -$165.8 million in 2023, then surged by 555.70% to $755.6 million in 2024.